Catheter Precision - VTAK STOCK NEWS

Catheter Precision (NYSE/American:VTAK) announced its participation in the 15th International Symposium on Catheter Ablation Techniques (ISCAT) from October 16-18 in Paris, France. ISCAT is a biannual European meeting focusing on new and emerging catheter ablation technologies, techniques, and study data for atrial and ventricular arrhythmias.

CEO David Jenkins emphasized the importance of attending such meetings as part of their sales strategy, stating that it provides an opportunity to meet physicians, showcase technologies, and generate new sales leads. At ISCAT, Catheter Precision plans to demonstrate their VIVO technology and highlight recent clinical data presented at the European Society of Cardiology meeting in September, which demonstrates VIVO's value and accuracy.

Catheter Precision, Inc. (NYSE/American:VTAK), a US-based medical device company specializing in cardiac electrophysiology products, has announced its participation in the 19th annual International VT Symposium on October 11-12 in New York City. The symposium, hosted by the Hospital at the University of Pennsylvania and Mount Sinai Hospital, focuses on new management strategies for ventricular arrhythmias, including nonpharmacological therapies like implantable devices and catheter ablation techniques.

David Jenkins, CEO of Catheter Precision, emphasized the importance of this event, stating it provides an opportunity to interact with a specialized group of physicians treating ventricular arrhythmias. The company's VIVO product enables better planning of ventricular ablation procedures, potentially reducing procedural time and patient complications. Catheter Precision aims to share new data and product improvements with attendees during the symposium.

Catheter Precision (NYSE/American:VTAK) has announced updates for their VIVO non-invasive mapping system. At the European Society of Cardiology (ESC) meeting, Prof. Tarv Dhanjal presented data from a 20-patient study, showing 90% procedural success at a mean follow-up of 7.3 ± 4.7 months in patients with scar-related VT. The full study, expected to enroll 50 patients, is anticipated to conclude in 2025.

Catheter Precision will showcase VIVO at several conferences in October, including the International VT Symposium, ISCAT, and SCRN. The company is expanding its commercial footprint, with over 25 centers confirming interest and eight new centers scheduled for evaluations. Additionally, following a successful evaluation in Doha, Qatar, the hospital has acquired and installed the VIVO system, completing its first commercial procedures.

Catheter Precision, Inc. (VTAK:NYSE/American) has announced the issuance of its first LockeT patent in China. LockeT is a suture retention device used for closing percutaneous catheter access sites during various procedures, including electrophysiology, structural heart, and vascular surgery. The device is currently sold in the US and select international markets.

The company is awaiting CE mark certification, expected in Q1 2025, which will allow access to the European market. CEO David Jenkins highlighted China as a significant market for LockeT, citing its low-cost alternative status and clinical data demonstrating ease of use, patient comfort, and effectiveness in groin management, including early ambulation and same-day discharge.

Catheter Precision, Inc. (NYSE American: VTAK), a US-based medical device company specializing in electrophysiology products, has expanded its LockeT distribution to the Middle East. The company has signed a distribution agreement with Dubai-based Forum Medical, which includes partnerships with additional distributors in Georgia, Uzbekistan, and Kazakhstan.

LockeT is described as a safe, low-cost device that provides quick hemostasis after venous access, reducing time and staff-related burdens. CEO David Jenkins highlighted the product's high demand in both international and US markets, expressing excitement about introducing this unique tool to physicians in new regions.

Catheter Precision, Inc. (NYSE American: VTAK), a US-based medical device company specializing in cardiac electrophysiology, has announced its first purchase order for LockeT from the Pacific Northwest territory. The order comes from the MultiCare Health System, which operates 300 specialty care locations and twelve hospitals across Washington State, Idaho, and Oregon.

This development follows the company's recent expansion of its US sales and clinical team in preparation for the national product launch of LockeT. CEO David Jenkins expressed satisfaction with the continued growth from new hospitals and territories throughout the US, attributing it to the new sales, marketing, and growth strategy implemented earlier this year for LockeT.

Catheter Precision, Inc. (NYSE American:VTAK) announced interim results from a study presented at the European Society of Cardiology (ESC) Symposium. The study, led by Professor Tarv Dhanjal at Warwick Medical School, demonstrated the accuracy of VIVO in localizing ventricular tachycardia (VT) origin in patients with scar-related re-entrant VT. Key findings include:

- 90% accuracy of VIVO compared to invasive mapping
- Significant match in myocardial scar areas
- 90% procedural success at 7-month follow-up
- Study included patients with various cardiomyopathies and mean ejection fraction of 35.5%

CEO David Jenkins highlighted the significance of these results for treating complex cardiac patients and expressed hope for expanded indications in the US.

Catheter Precision, Inc. (NYSE American:VTAK), a MedTech company specializing in cardiac electrophysiology, has announced its first purchase order for LockeT from a hospital in the greater Chicago area. This order comes from one of the hospitals within the Endeavor Health System, the third largest healthcare system in Illinois with 9 hospitals, over 300 care sites, and more than 7,100 physicians.

The company recently expanded its US sales and clinical team in preparation for LockeT's national product launch. Marie-Claude Jaques, Chief Commercial Officer, expressed optimism about the company's sales infrastructure and anticipates more purchase orders in the coming months. This development aligns with Catheter Precision's goal to bring LockeT's potential benefits to patients, physicians, and hospitals across the US.

Catheter Precision (NYSE American:VTAK) has closed its public offering of 805,900 common stock units and 2,773,000 pre-funded warrant units, priced at $1.00 and $0.9999 per unit respectively. The offering includes 458,623 common stock units issued upon exercise of the underwriters' over-allotment option. Each unit consists of one share (or pre-funded warrant), and three warrants (Series H, I, and J) with varying expiration dates. The total gross proceeds amount to $3.6 million. Ladenburg Thalmann & Co. acted as the sole book-running manager for this offering, which was conducted pursuant to effective registration statements filed with the SEC.